LINCS Pilot Phase Joint Project: Sensitivity measures of six breast cancer cell lines to a library of small molecule kinase inhibitors (single drug treatments). Dataset 2 of 15: Cell count and relative growth within biological replicate 2. - Dataset (ID:20238)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Small Molecule | Small Mol Concentration | Small Mol Conc Unit | LJP Library Plate | Replicate | Assay Well | Timepoint | Timepoint Unit | Total Cell Count Before Treatment | Total Cell Count After Treatment | Total Control Cell Count | Relative Cell Count | Relative Growth Rate After Treatment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SK-BR-3 | LDN-193189 | 1.11 | uM | LJP5 | 3 | G03 | 72 | hr | 2543 | 6339 | 5578 | 1.1363 | 1.2505 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 1 | J09 | 72 | hr | 2543 | 5619 | 5578 | 1.0072 | 1.0133 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 2 | J09 | 72 | hr | 2543 | 5172 | 5578 | 0.9271 | 0.8660 |
| SK-BR-3 | Linifanib | 1.11 | uM | LJP6 | 3 | J09 | 72 | hr | 2543 | 5734 | 5578 | 1.0278 | 1.0512 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 1 | O21 | 72 | hr | 2543 | 4921 | 5578 | 0.8821 | 0.7833 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 2 | O21 | 72 | hr | 2543 | 4828 | 5578 | 0.8654 | 0.7527 |
| SK-BR-3 | Linsitinib | 1.11 | uM | LJP5 | 3 | O21 | 72 | hr | 2543 | 5291 | 5578 | 0.9484 | 0.9052 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 1 | C21 | 72 | hr | 2543 | 1709 | 5578 | 0.3064 | -0.2749 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 2 | C21 | 72 | hr | 2543 | 1595 | 5578 | 0.2859 | -0.3125 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP5 | 3 | C21 | 72 | hr | 2543 | 1796 | 5578 | 0.3219 | -0.2463 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 1 | C21 | 72 | hr | 2543 | 1357 | 5578 | 0.2433 | -0.3909 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 2 | C21 | 72 | hr | 2543 | 1362 | 5578 | 0.2441 | -0.3893 |
| SK-BR-3 | Mitoxantrone | 1.11 | uM | LJP6 | 3 | C21 | 72 | hr | 2543 | 1380 | 5578 | 0.2474 | -0.3833 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 1 | F03 | 72 | hr | 2543 | 3624 | 5578 | 0.6496 | 0.3560 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 2 | F03 | 72 | hr | 2543 | 3541 | 5578 | 0.6347 | 0.3287 |
| SK-BR-3 | MK2206 | 1.11 | uM | LJP6 | 3 | F03 | 72 | hr | 2543 | 3667 | 5578 | 0.6573 | 0.3702 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 1 | A15 | 72 | hr | 2543 | 1453 | 5578 | 0.2605 | -0.3593 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 2 | A15 | 72 | hr | 2543 | 1417 | 5578 | 0.2540 | -0.3711 |
| SK-BR-3 | Neratinib | 1.11 | uM | LJP5 | 3 | A15 | 72 | hr | 2543 | 1543 | 5578 | 0.2766 | -0.3296 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 1 | N15 | 72 | hr | 2543 | 6209 | 5578 | 1.1130 | 1.2077 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 2 | N15 | 72 | hr | 2543 | 6198 | 5578 | 1.1110 | 1.2040 |
| SK-BR-3 | Nilotinib | 1.11 | uM | LJP5 | 3 | N15 | 72 | hr | 2543 | 5962 | 5578 | 1.0687 | 1.1263 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 1 | H03 | 72 | hr | 2543 | 5022 | 5578 | 0.9002 | 0.8166 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 2 | H03 | 72 | hr | 2543 | 4963 | 5578 | 0.8896 | 0.7972 |
| SK-BR-3 | Nintedanib | 1.11 | uM | LJP6 | 3 | H03 | 72 | hr | 2543 | 5001 | 5578 | 0.8965 | 0.8097 |